These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 39247984)

  • 1. Changes of clinical characteristics, distribution of red flags and prognosis in contemporary patients with wild-type transthyretin amyloidosis cardiomyopathy.
    Sanne Bøjet L; Bertil L; Anders Lehmann Dahl P; Jens Kæstel S; Tor Skibsted C; Steen Hvitfeldt P
    Ann Med; 2024 Dec; 56(1):2398735. PubMed ID: 39247984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study.
    Aimo A; Vergaro G; Castiglione V; Fabiani I; Barison A; Gentile F; Ferrari Chen YF; Giorgetti A; Genovesi D; Buda G; Franzini M; Piepoli M; Moscardini S; Rapezzi C; Fontana M; Passino C; Emdin M
    Eur J Prev Cardiol; 2024 Aug; 31(11):1410-1417. PubMed ID: 38456769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of survival stratification in patients with wild-type cardiac amyloidosis.
    Siepen FAD; Bauer R; Voss A; Hein S; Aurich M; Riffel J; Mereles D; Röcken C; Buss SJ; Katus HA; Kristen AV
    Clin Res Cardiol; 2018 Feb; 107(2):158-169. PubMed ID: 28956153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems.
    Cappelli F; Martone R; Gabriele M; Taborchi G; Morini S; Vignini E; Allinovi M; Di Gioia M; Bartolini S; Di Mario C; Perfetto F
    Can J Cardiol; 2020 Mar; 36(3):424-431. PubMed ID: 32145869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and predictors of worsening heart failure in patients with wild-type transthyretin cardiac amyloidosis.
    Ladefoged BT; Dybro A; Dahl Pedersen AL; Rasmussen TB; Vase HØ; Clemmensen TS; Gillmore J; Poulsen SH
    ESC Heart Fail; 2022 Oct; 9(5):2978-2987. PubMed ID: 35733407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exercise Hemodynamics and Mitochondrial Oxidative Capacity in Disease Stages of Wild-Type Transthyretin Amyloid Cardiomyopathy.
    Ladefoged B; Pedersen AD; Seefeldt J; Nielsen BRR; Eiskjær H; Lichscheidt E; Clemmensen T; Gillmore JD; Poulsen SH
    J Am Heart Assoc; 2024 Jul; 13(13):e034213. PubMed ID: 38934860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence, clinical significance and prognosis value of liver stiffness measurement anomalies in transthyretin cardiac amyloidosis.
    Lointier E; Cariou E; Beneyto M; Fournier P; Lavie-Badie Y; Eyharts D; Bureau C; Lairez O;
    Int J Cardiol; 2024 Dec; 416():132485. PubMed ID: 39187068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac amyloidosis is not a single disease: a multiparametric comparison between the light chain and transthyretin forms.
    Neculae G; Adam R; Jercan A; Bădeliță S; Tjahjadi C; Draghici M; Stan C; Bax JJ; Popescu BA; Marsan NA; Coriu D; Jurcuț R
    ESC Heart Fail; 2024 Oct; 11(5):2825-2834. PubMed ID: 38757395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and natural history of early-stage cardiac transthyretin amyloidosis.
    Law S; Bezard M; Petrie A; Chacko L; Cohen OC; Ravichandran S; Ogunbiyi O; Kharoubi M; Ganeshananthan S; Ganeshananthan S; Gilbertson JA; Rowczenio D; Wechalekar A; Martinez-Naharro A; Lachmann HJ; Whelan CJ; Hutt DF; Hawkins PN; Damy T; Fontana M; Gillmore JD
    Eur Heart J; 2022 Jul; 43(27):2622-2632. PubMed ID: 35608040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System.
    Grogan M; Scott CG; Kyle RA; Zeldenrust SR; Gertz MA; Lin G; Klarich KW; Miller WL; Maleszewski JJ; Dispenzieri A
    J Am Coll Cardiol; 2016 Sep; 68(10):1014-20. PubMed ID: 27585505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid cardiomyopathy in a large integrated health care system.
    Czobor P; Hung YY; Baer D; McGlothlin D; Weisshaar D; Zaroff J
    Am Heart J; 2019 Oct; 216():42-52. PubMed ID: 31401442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and imaging characteristics of patients with cardiac amyloidosis- a single center observational study.
    Ingebrigtsen A; Saeed S; Larsen TH; Reikvam H
    Scand J Clin Lab Invest; 2024 May; 84(3):193-201. PubMed ID: 38709651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
    Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
    Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in the diagnostic trajectory of transthyretin cardiac amyloidosis over six years.
    Achten A; van Empel VPM; Weerts J; Mourmans S; Beckers-Wesche F; Spanjers M; Gingele A; Brunner-La Rocca HP; Sanders-van Wijk S; Knackstedt C
    Heart Vessels; 2024 Oct; 39(10):857-866. PubMed ID: 38710807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new staging system for cardiac transthyretin amyloidosis.
    Gillmore JD; Damy T; Fontana M; Hutchinson M; Lachmann HJ; Martinez-Naharro A; Quarta CC; Rezk T; Whelan CJ; Gonzalez-Lopez E; Lane T; Gilbertson JA; Rowczenio D; Petrie A; Hawkins PN
    Eur Heart J; 2018 Aug; 39(30):2799-2806. PubMed ID: 29048471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of wild-type transthyretin cardiac amyloidosis in patients with carpal tunnel syndrome surgery (CACTuS).
    Ladefoged B; Clemmensen T; Dybro A; Hartig-Andreasen C; Kirkeby L; Gormsen LC; Bomholt P; Gillmore J; Poulsen SH
    ESC Heart Fail; 2023 Feb; 10(1):234-244. PubMed ID: 36193570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
    Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
    JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis.
    Damy T; Deux JF; Moutereau S; Guendouz S; Mohty D; Rappeneau S; Guellich A; Hittinger L; Loric S; Lefaucheur JP; Plante-Bordeneuve V
    Amyloid; 2013 Dec; 20(4):212-20. PubMed ID: 23964755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
    Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
    JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive risk stratification of patients with transthyretin amyloidosis.
    Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
    JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.